InSilico Medicine Cayman TopCo (FRA:O15) Total Assets: €418.45 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Total Assets?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 Total Assets is €418.45 Mil as of Dec. 2025. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's Total Assets for the quarter that ended in Dec. 2025 was €418.45 Mil.

During the past 12 months, InSilico Medicine Cayman TopCo's average Total Assets Growth Rate was 136.70% per year. During the past 3 years, the average Total Assets Growth Rate was 16.60% per year.

During the past 4 years, InSilico Medicine Cayman TopCo's highest 3-Year average Total Assets Growth Rate was 16.60%. The lowest was 16.60%. And the median was 16.60%.

Total Assets is connected with ROA %. InSilico Medicine Cayman TopCo's annualized ROA % for the quarter that ended in Dec. 2025 was -181.29%. Total Assets is also linked to Revenue through Asset Turnover. InSilico Medicine Cayman TopCo's Asset Turnover for the quarter that ended in Dec. 2025 was 0.08.


InSilico Medicine Cayman TopCo  (FRA:O15) Total Assets Explanation

Total Assets is connected with ROA %.

InSilico Medicine Cayman TopCo's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-568.936/( (209.217+418.445)/ 2 )
=-568.936/313.831
=-181.29 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

InSilico Medicine Cayman TopCo's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=24.581/( (209.217+418.445)/ 2 )
=24.581/313.831
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

InSilico Medicine Cayman TopCo Total Assets Related Terms


InSilico Medicine Cayman TopCo Total Assets Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Total Assets Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Assets
221.64 185.96 137.52 418.45

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial 185.96 0.00 137.52 209.22 418.45
FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

InSilico Medicine Cayman TopCo's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=386.03+32.415
=418.45

InSilico Medicine Cayman TopCo's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=386.03+32.415
=418.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €418.45 Mil mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Total Assets of €418.45 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Total Assets too high?
InSilico Medicine Cayman TopCo's current Total Assets is €418.45 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Total Assets compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's Total Assets of €418.45 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Software company?
A good Total Assets depends on the Software industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Total Assets is €418.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Total Assets of €418.45 Mil. The current Total Assets is €418.45 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Total Assets is €418.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price